These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3441450)

  • 21. Sedative action of cholecystokinin octapeptide on behavioral excitation by thyrotropin releasing hormone and methamphetamine in the rat.
    Katsuura G; Itoh S
    Jpn J Physiol; 1982; 32(1):83-91. PubMed ID: 6281507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L364,718 antagonizes the cholecystokinin-induced suppression of locomotor activity.
    Soar J; Hewson G; Leighton GE; Hill RG; Hughes J
    Pharmacol Biochem Behav; 1989 Jul; 33(3):637-40. PubMed ID: 2587606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of injection of CCK-8 into the nucleus caudatus on the behavior of rats.
    Takeda Y; Kamiya Y; Honda K; Takano Y; Kamiya H
    Jpn J Pharmacol; 1986 Apr; 40(4):569-75. PubMed ID: 3735805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholecystokinin facilitates ejaculation in male rats: blockade with proglumide and apomorphine.
    Pfaus JG; Phillips AG
    Eur J Pharmacol; 1987 Sep; 141(3):331-8. PubMed ID: 3666030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracerebroventricular cholecystokinin infusions block beta-endorphin-induced disruption of maternal behavior.
    Felicio LF; Mann PE; Bridges RS
    Pharmacol Biochem Behav; 1991 May; 39(1):201-4. PubMed ID: 1924504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitize a morphine-induced excitatory response.
    Felicio LF; Mazzini BK; Cacheiro RG; Cruz TN; Flório JC; Nasello AG
    Peptides; 2001 Aug; 22(8):1299-304. PubMed ID: 11457524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholecystokinin tetrapeptide, proglumide and open-field behavior in rats.
    Hsiao S; Katsuura G; Itoh S
    Life Sci; 1984 May; 34(22):2165-8. PubMed ID: 6727557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal by cholecystokinin of apomorphine-induced inhibition of dopamine release in the nucleus accumbens of the rat.
    Blaha CD; Phillips AG; Lane RF
    Regul Pept; 1987 Jun; 17(6):301-10. PubMed ID: 3602473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asymmetry in behavioral responses to cholecystokinin microinjected into rat nucleus accumbens and amygdala.
    Belcheva I; Belcheva S; Petkov VV; Petkov VD
    Neuropharmacology; 1994 Aug; 33(8):995-1002. PubMed ID: 7845556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circling behavior following unilateral microinjections of cocaine into the medial prefrontal cortex: dopaminergic or local anesthetic effect?
    Morency MA; Stewart RJ; Beninger RJ
    J Neurosci; 1987 Mar; 7(3):812-8. PubMed ID: 3559712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specificity of nucleus accumbens to activities related to cholecystokinins in rats.
    Katsuura G; Itoh S; Hsiao S
    Peptides; 1985; 6(1):91-6. PubMed ID: 3991366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of different subtypes of cholecystokinin receptors in opioid antinociception in the mouse.
    Suh HW; Kim YH; Choi YS; Song DK
    Peptides; 1995; 16(7):1229-34. PubMed ID: 8545243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered responding to cholecystokinins and dopaminergic agonists following 6-hydroxydopamine treatment in rats.
    Hsiao S; Katsuura G; Itoh S
    Behav Neurosci; 1985 Oct; 99(5):853-60. PubMed ID: 3939625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.
    Weiss F; Ettenberg A; Koob GF
    Psychopharmacology (Berl); 1989; 99(3):409-15. PubMed ID: 2574480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracerebroventricular administration of cholecystokinin reduces stereotypy in dopamine-supersensitive rats.
    Tieppo CA; Silva AM; Palermo-Neto J; Nasello AG; Felicio LF
    Braz J Med Biol Res; 1995 Mar; 28(3):351-4. PubMed ID: 8520531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of central nervous system cholecystokinin receptors stimulates respiration in the cat.
    Gillis RA; Quest JA; Pagani FD; Souza JD; Da Silva AM; Jensen RT; Garvey TQ; Hamosh P
    J Pharmacol Exp Ther; 1983 Feb; 224(2):408-14. PubMed ID: 6296361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intracerebroventricular administration of two molecular forms of sulfated CCK octapeptide on anxiety-like behavior in the zebrafish danio rerio.
    Matsuda K; Yoshida D; Sachuriga ; Watanabe K; Yokobori E; Konno N; Nakamachi T
    Peptides; 2020 Aug; 130():170330. PubMed ID: 32445877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of intraventricular administration of cholecystokinin octapeptide sulfate ester and unsulfated cholecystokinin octapeptide on active avoidance and conditioned feeding behaviour of rats.
    Fekete M; Szabó A; Balázs M; Penke B; Telegdy G
    Acta Physiol Acad Sci Hung; 1981; 58(1):39-45. PubMed ID: 6282048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholecystokinin and an evoked response in the dentate gyrus.
    Sinton CM
    Neuropeptides; 1988 Jul; 12(1):29-34. PubMed ID: 3419558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.